(Q38073889)

28 August 2017

1 reference

title

Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions (English)

1 reference

glucocorticoid-induced osteoporosis

28 August 2017

0 references

0 references

1 reference

Irene E M Bultink

1

1 reference

28 August 2017

Marijke Baden

series ordinal

2

1 reference

28 August 2017

Willem F Lems

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

14 January 2013

1 reference

Expert Opinion on Pharmacotherapy

28 August 2017

published in

1 reference

28 August 2017

volume

14

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

185-197

1 reference

A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Clinical practice. Glucocorticoid-induced bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Advances in glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Glucocorticoid-induced osteoporosis: pathophysiology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

How antirheumatic drugs protect joints from damage in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

From bone biology to clinical outcome: state of the art and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Rheumatoid arthritis, corticosteroid therapy and hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Use of oral corticosteroids and risk of fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Fracture risk with intermittent high-dose oral glucocorticoid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Assessment of fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Use of oral corticosteroids in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Clinical question: What is the best approach to managing glucocorticoid-induced osteoporosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Prevention of glucocorticoid-induced apoptosis in osteocytes and osteoblasts by calbindin-D28k

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase 3beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Silencing Dkk1 expression rescues dexamethasone-induced suppression of primary human osteoblast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Tandem repeat of C/EBP binding sites mediates PPARgamma2 gene transcription in glucocorticoid-induced adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Regulation of human bone marrow stromal cell proliferation and differentiation capacity by glucocorticoid receptor and AP-1 crosstalk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Glucocorticoids suppress bone formation via the osteoclast

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Relative value of 25(OH)D and 1,25(OH)2D measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

The Comparative Efficacy of Drug Therapies Used for the Management of Corticosteroid-Induced Osteoporosis: A Meta-Regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Incidence of atypical nontraumatic diaphyseal fractures of the femur

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Compliance and persistence with osteoporosis medications: a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Adherence and profile of non-persistence in patients treated for osteoporosis—a large-scale, long-term retrospective study in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Oral bisphosphonate compliance and persistence: a matter of choice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Preferences of GPs and patients for preventive osteoporosis drug treatment: a discrete-choice experiment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Inflammatory rheumatic disorders and bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Anabolic therapy in glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761975

10.1517/14656566.2013.761975

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference